




## KAI

# COVID 19



Μαρία Γεωργίου  
LERIVA DIAGNOSTICS



**CYTOMETRY**  
Journal of Quantitative Cell Science PART A




# **SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health**

**Andrea Cossarizza,<sup>1\*</sup> Sara De Biasi,<sup>1†</sup> Giovanni Guaraldi,<sup>2</sup> Massimo Girardis,<sup>3</sup>  
Cristina Mussini,<sup>2</sup> for the Modena Covid-19 Working Group (MoCo19)<sup>#</sup>**



• **Key terms**

SARS-CoV-2; Covid-19; coronavirus; cytometry; CD4; CD8; T cells


(b)






(a)



***CD3+, CD4+ CTRL***



***CD3+, CD4+ COVID-19***



# DURAClone\* & DURActive\* Product Families


DURAClone IF T Helper Cell

DURAClone IF T Activation Tube

DURAClone IM Treg Tube

DURAClone IM T cell subsets

405 excitation		480 excitation					633 excitation		
Pacific Blue	Krome Orange	FITC	PE	ECD	PC5.5	PC7	APC	APC-A700	APC-A750
IL-17		IFN- $\gamma$				IL-4	CD4		CD3
CD4		IFN- $\gamma$	TNF $\alpha$			IL-2		CD8	CD3
Helios	CD45	CD45RA	CD25		CD39	CD4	FoxP3		CD3
CD57	CD45	CD45RA	CD197	CD28	CD279	CD27	CD4	CD8	CD3





# DURAClone\* & DURActive\* Product Families

## **DURActive 1 25 tests RUO C11101**


Dry Stimulation Mixes for Immune Functional Assays  
PMA, Ionomycin, Brefeldin A

## **DURActive 2 25 tests RUO C11102**

Dry Stimulation Mixes for Immune Functional Assays  
PMA, Ionomycin

## **DURActive 3 25 tests RUO C21857**

Dry Stimulation Mixes for Immune Functional Assays  
LPS, Brefeldin A




## REVIEW ARTICLE



# CYTOMETRY

Journal of Quantitative Cells Science P A R T A




### Relevance of Antibody Validation for Flow Cytometry

Tomas Kalina,<sup>1\*</sup> Kelly Lundsten,<sup>2</sup> Pablo Engel<sup>3</sup>


Thus, at present, **multiparametric cytometry assays require antibody conjugates with known performance criteria under several conditions**; for several cell types, validation data shall be presented for monoclonal antibody reactivity and for antibody conjugate performance. **Consensus on benchmarking methods**, aggregation of comparable data sets across manufacturers and users and public availability of the performance data on clones as well as on antibody conjugates will lead to a qualitatively higher level of information generated by flow cytometry and to a further spread of its applications to basic, translational, and clinical research.

UMAP2

## CD3+,CD4+ T CELLS




- NAIVE
- NAIVE,CD38+
- TREG NAIVE,DR+
- CM
- CM,CD38+
- CM,PD1+
- TM
- TREG EM,DR+
- EM
- ACTIVATED EM
- EM,PD1+,CD57+
- EMRA,PD1+,CD57+




UMAP2

## CD3+,CD8+ T CELLS




- NAIVE
- NAIVE,CD38+
- NAIVE,DR+
- CM
- CM,CD38+
- TM
- EM
- ACTIVATED EM, PD1+
- EM,CD57+
- EMRA
- ACTIVATED, EMRA
- EMRA, CD57+
- TM,DR+



**Figure 1.** Differentiation, activation and exhaustion of CD4+ or CD8+ T-cell subsets in patients with Covid-19. Representation of an 18-parameter analysis of peripheral blood cells. Cells were stained with the Duraclone IM T cell panel (from Beckman Coulter, FL, USA) added with another five fluorescent mAbs and a marker of cell viability and analyzed on a CytoFLEX LX flow cytometer (Beckman Coulter). Beside side and forward scatters, markers were CD45 conjugated with Krome Orange, CD3 APC-A750, CD4 APC, CD8 AF700, CD27 PC7, CD57 Pacific Blu, CD279 (PD-1) PC5.5, CD28 ECD, CCR7 PE, CD45RA FITC, HLA-DR BUV661, CD127 BV650, CD25 BV785, CD95 BUV395, CD38 BUV496, and PromoFluor-840 (Promokine). Unsupervised analysis of electronically gated CD45+, CD3+, CD4+ or CD45+, CD3+, CD8+ T-cells was first performed by using the Catalyst package (Bioconductor) (16). Second, for both CD4+ and CD8+ T-cell analysis, 10,000 cells per sample were concatenated and transformed. FlowSOM was used to perform the metaclustering ( $K = 20$ ); then, data were represented by the dimensionality reduction method named Uniform Manifold Approximation and Projection (UMAP). It is possible to observe the presence of 12 clusters among CD4+ and 13 among CD8+ T-cells and to see the high amount of naive cells in both T cell populations, and how the distribution of naive, memory, activated and exhausted lymphocytes is different among different types of CD4+ or CD8+ T lymphocytes.



# Unsupervised and Supervised Machine Learning Algorithms in Cytobank



- 1) Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and Immunologic features in severe and moderate Coronavirus Disease 2019. *J Clin Invest*. 2020.
- 2) Fan Wang, Jiayan Nie, Haizhou Wang, Qiu Zhao, Yong Xiong, Liping Deng, Shihui Song, Zhiyong Ma, Pingzheng Mo, Yongxi Zhang, Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia, *The Journal of Infectious Diseases*, , jiaa150, <https://doi.org/10.1093/infdis/jiaa150>
- 3) Wherry, E. T cell exhaustion. *Nat Immunol* **12**, 492–499 (2011).  
<https://doi.org/10.1038/ni.2035>
- 4) Cossarizza, A., De Biasi, S., Guaraldi, G., Girardis, M., Mussini, C. and (2020), SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. *Cytometry*, 97: 340-343. doi:[10.1002/cyto.a.24002](https://doi.org/10.1002/cyto.a.24002)
- 5) Tay, M.Z., Poh, C.M., Rénia, L. *et al*. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* (2020).  
<https://doi.org/10.1038/s41577-020-0311-8>